Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Rank in Stocks #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Share Price
$193.62
Market Cap
$150.08B
Change (1 day)
2.76%
Change (1 year)
184.69%
Country
GB
Trade AstraZeneca PLC (AZN)

Category

Operating Margin for AstraZeneca PLC (AZN)
Operating Margin as of April 2026 TTM: 23.28%
According to AstraZeneca PLC latest financial reports and stock price the company's current Operating Margin (TTM) is 23.28%. At the end of 2023 the company had an Operating Margin of 20.54%.
Operating Margin history for AstraZeneca PLC from 2000 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 23.28% -1.56%
2024 23.65% 15.14%
2023 20.54% 80.02%
2022 11.41% 50.73%
2021 7.57% -55.42%
2020 16.98% 47.52%
2019 11.51% 38.51%
2018 8.31% -46.21%
2017 15.45% -0.26%
2016 15.49% 6.90%
2015 14.49% 3.95%
2014 13.94% -41.77%
2013 23.94% -24.38%
2012 31.66% -12.49%
2011 36.18% -4.69%
2010 37.96% 8.15%
2009 35.10% 11.39%
2008 31.51% 11.78%
2007 28.19% -3.85%
2006 29.32% 9.73%
2005 26.72% 31.24%
2004 20.36% -6.65%
2003 21.81% -10.69%
2002 24.42% 1.79%
2001 23.99% 18.59%
2000 20.23% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
45.56% -98.04%
US
27.17% -98.83%
US
26.72% -98.85%
US
31.24% -98.66%
CH
41.19% -98.23%
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.